Stock Update (NYSE:BMY): FDA approves new Bristol-Myers treatment for multiple myeloma

[Reuters] – The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The . . . → Read More: Stock Update (NYSE:BMY): FDA approves new Bristol-Myers treatment for multiple myeloma Similar Articles: Company Update: AbbVie Inc (NYSE:ABBV) – Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – FDA approves expanded use of Bristol-Myers’ skin cancer drug Stock Update (NYSE:BMY): FDA approves Bristol Myers’ combination treatment for skin cancer